Mitochon Pharmaceuticals: New Compound Gets Orphan Drug Status for Huntington's Disease

Mitochon Pharmaceuticals' MP-101 has received an orphan drug designation from the FDA for the treatment of Huntington's disease. The company said that MP-101-a mitochondrial targeted compound-has been shown to protect both spiny neurons and general neurons and minimize brain-volume loss in patients with Huntington's disease. Combined, these effects could significantly alter the disease's progression in patients.